Oncology + Anti-Viruses (COVID-19, Influenza, Zika, ...)Shortly, we will know where we stand regarding 2 pivotal indications, when we get:
- clinical data (oncology) from our pivotal NMIBC Ph. 2
- preclinical data (anti-virus) from the High Containment Respiratory Virus Group, Special Pathogens, National Microbiology Laboratory (NML), Public Health Agency of Canada (“PHAC”) for the research and development of a Canadian-based SARS-CoV-2 (“COVID-19”) vaccine and other enveloped viruses (influenza, Zika, herpes simplex, SARS-COV-2, MonkeyPox)
Excellent results on these 2 fronts and this could redefine this company.
Considering all that's been done so far (TLD1433, working with the credible NML, etc ...), it is reasonable to expect positive outcome on both fronts. But only data will confirm this. Nothing else.